Kymera Therapeutics, a company focused on immunology, has accelerated the Phase IIb readout for its lead drug KT-621 to Q4 2024, previously targeted for mid-2027. The company presented its findings at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24, 2026.
The KT-621 Phase IIb trial, named BROADEN 2, will enroll more than 200 patients for at least 16 weeks and test three dose levels. The trial includes adolescent patients as part of a parallel pediatric strategy. The company aims to achieve a mid-2025 timeline from the end-of-phase-II meeting to the first patient dosed in phase III.
Kymera Therapeutics' CEO, Nello Mainolfi, emphasized the company's focus on quality over speed. He stated, "Our goal has always been quality over speed, and never compromise quality for speed. That makes actually the pace of enrollment much more impactful."
The company's pipeline includes KT-579, an IRF5 degrader, with Phase I data expected soon before the KT-621 BROADEN 2 readout. Systemic lupus erythematosus (SLE) is likely to be the first proof-of-concept indication for KT-579.
Kymera Therapeutics is targeting atopic dermatitis as its lead indication, with asthma as the major next step. The company also has high-priority gastroenterology targets, including eosinophilic esophagitis, and is preparing for chronic rhinosinusitis with nasal polyps. COPD is a potential future expansion area.
The company's Chief Medical Officer, Terence Rooney, discussed the potential of oral therapies, citing Otezla and Icotinib as examples of successful oral therapies with lower efficacy than biologics. He noted, "Safe, effective oral does not have to look like injectable biologics. Otezla, 50% the efficacy of biologics, multibillion-dollar drug. Icotinib, 20%, 30% less efficacious than biologics."
Kymera Therapeutics' stock was trading at $117.67 on September 23, 2026, down 0.08 or -0.07%. The company has a long-term goal to address 4 to 5 major indications representing more than 90% of type 2 disease revenues.
The U.S. moderate-to-severe atopic dermatitis population is estimated at 6 million to 9 million patients, with only about 400,000 patients, or roughly 5% penetration, currently treated with advanced systemic therapies.
